Table 2.
Main rheumatic diseases and concomitant medication at baseline
| N (%) | |
|---|---|
| Rheumatic disease | |
| Systemic lupus erythematous | 4243 (82.5) |
| Rheumatoid arthritis | 402 (7.8) |
| Primary Sjögren syndrome | 192 (3.7) |
| Mixed connective tissue disease | 75 (1.5) |
| Osteoarthritis | 66 (1.3) |
| Systemic sclerosis | 43 (0.8) |
| Inflammatory myopathies | 34 (0.7) |
| Chikungunya | 18 (0.4) |
| Other | 69 (1.3) |
| Antimalarials | |
| Hydroxychloroquine (HCQ) | 5035 (97.5) |
| HCQ use time (years), mean (SD) | 7.2 (6.2) |
| Chloroquine diphosphate (CD) | 131 (2.5) |
| CD use time (years), mean (SD) | 10.6 (7.4) |
| Concomitant medication related to RD | |
| Glucocorticoids | 1895 (36.7) |
| < 10 mg/day | 1394 (73.6) |
| ≥ 10 mg/day | 462 (24.4) |
| Ibuprofen | 35 (0.7) |
| IV Methylprednisolone (pulse) | 30 (0.6) |
| Cyclophosphamide (oral and pulse) | 73 (1.4) |
| Synthetic conventional DMARDs | 2444 (47.3) |
| Methotrexate | 631 (12.2) |
| Sulfasalazine | 16 (0.3) |
| Azathioprine | 983 (19.0) |
| Leflunomide | 96 (1.9) |
| Cyclosporine | 80 (1.5) |
| Mycophenolate mofetil | 657 (12.7) |
| Biological or target-specific DMARDs | 181 (3.5) |
| TNF inhibitors | 17 (0.3) |
| Belimumab | 52 (1.0) |
| Rituximab | 81 (1.6) |
| Abatacept | 17 (0.3) |
| Tocilizumab | 7 (0.1) |
| Tofacitinib | 7 (0.1) |
The results are expressed as means, standard deviation and percentages; DMARDs, disease activity-modifying drugs; some individuals are taking more than one synthetic DMARD